With a streamlined regulatory environment, including no requirement for an IND, and the supportive R&D Government refund of up to 43.5% on clinical research spend, Australia has become a preferred destination for early phase clinical trials.

The number of clinical trials has grown solidly in the last few years in Australia, enjoying over 10% growth per annum between 2016 and 2018.

Other relevant content